New pill targets Tough-to-Treat blood cancers in early trial

NCT ID NCT07155226

Recruiting now Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This early-stage study is testing a new oral drug called AZD3632 for people with advanced blood cancers like leukemia and myelodysplastic syndromes that have returned or stopped responding to standard treatments. The main goals are to find a safe dose, see how the body processes the drug, and check for early signs that it might help control the disease. The study will test the drug alone and in combination with another medication.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Research Site
RECRUITING

Decatur, Illinois, 62526, United States
Research Site
NOT_YET_RECRUITING

New York, New York, 10065, United States
Research Site
RECRUITING

Durham, North Carolina, 27705, United States
Research Site
NOT_YET_RECRUITING

Portland, Oregon, 97239, United States
Research Site
RECRUITING

Houston, Texas, 77030, United States
Research Site
NOT_YET_RECRUITING

Fitzroy, 3065, Australia
Research Site
NOT_YET_RECRUITING

Perth, WA 6000, Australia
Research Site
NOT_YET_RECRUITING

Toronto, Ontario, M5G 2M9, Canada
Research Site
NOT_YET_RECRUITING

Montreal, Quebec, H3T 1E2, Canada
Research Site
RECRUITING

Copenhagen, 2100, Denmark
Research Site
RECRUITING

Dresden, 01307, Germany
Research Site
RECRUITING

Frankfurt A. Main, 60590, Germany
Research Site
RECRUITING

Halle, 06097, Germany
Research Site
RECRUITING

Heidelberg, 69120, Germany
Research Site
RECRUITING

München, 81377, Germany
Research Site
RECRUITING

Ulm, 89081, Germany
Research Site
RECRUITING

Bologna, 40138, Italy
Research Site
RECRUITING

Ravenna, 48121, Italy
Research Site
RECRUITING

Bunkyō City, 113-8677, Japan
Research Site
NOT_YET_RECRUITING

Kashiwa, 277-8577, Japan
Research Site
RECRUITING

Okayama, 700-8558, Japan
Research Site
RECRUITING

Seoul, 06351, South Korea
Research Site
RECRUITING

Seoul, 06591, South Korea
Research Site
RECRUITING

Seoul, 110-744, South Korea
Research Site
RECRUITING

Edinburgh, EH4 2XU, United Kingdom
Research Site
NOT_YET_RECRUITING

London, EC1A 7BE, United Kingdom
Research Site
RECRUITING

London, SE5 9RS, United Kingdom
Research Site
RECRUITING

Manchester, M20 4BX, United Kingdom
Research Site
NOT_YET_RECRUITING

Newcastle, NE7 7DN, United Kingdom

Conditions

Explore the condition pages connected to this study.

ACUTE LYMPHOBLASTIC LEUKAEMIA ACUTE MYELOID LEUKAEMIA HIGHER-RISK MYELODYSPLASTIC SYNDROMES